Merck (MRK) is back in focus after securing several major drug approvals and positive trial updates, along with an agreement to expand access to its new HIV treatment, IDVYNSO, through U.S. AIDS Drug Assistance Programs.

Merck’s recent string of approvals and positive trial readouts has coincided with firming momentum, with a 7.44% 7 day share price return and a 20.71% year to date share price return. The 1 year total shareholder return sits at 62.32%.

If progress in oncology, vaccines and HIV treatments has your attention, it can also be useful to look at other healthcare stocks using our focused screener for 40 healthcare AI stocks

With Merck stock up 20.71% year to date and trading close to the average analyst price target, while some models still suggest a sizable intrinsic discount, you have to ask: is there real upside left here, or is the market already pricing in the next leg of growth?

Most Popular Narrative: 100% Undervalued

On the most followed narrative, Merck’s fair value sits at $129.74, slightly above the last close at $128.50, yet still framed as meaningfully undervalued once future cash flows are considered.

With its acquisition and licensing strategy, Merck has nearly tripled its late-phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid-2030s, driving earnings growth. The ongoing strong launches of key new products, such as WINREVAIR and CAPVAXIVE, are positively impacting revenues and are expected to support further growth in the coming years.

Want to see what kind of revenue curve and profit profile this narrative is baking in, and how rich a future multiple it assumes on those earnings? The full story is in the detailed projections behind that fair value.

Result: Fair Value of $129.74 (UNDERVALUED)

However, Merck’s oncology-heavy story still hinges on key trial outcomes and the eventual loss of exclusivity for Keytruda, both of which could challenge the current earnings narrative.

Another View on Merck’s Valuation

While the SWS DCF model points to Merck trading 43.8% below an estimated future cash flow value of $228.62 per share, the market is currently attaching a P/E of 35.5x versus an estimated fair ratio of 32.5x and a US Pharmaceuticals average of 15.1x. Is the stock cheap on cash flows but rich on earnings multiples, or are both just reflecting different parts of the same story for you?

Next Steps

If the mixed signals on Merck’s risks and rewards leave you unsure, review the full picture and decide quickly where you stand with 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Merck?

Do not stop at Merck. Broaden your watchlist with fresh ideas that match your goals so you are not relying on a single story.

• Target potential mispricings by scanning for quality opportunities using our 43 high quality undervalued stocks.
• Strengthen your income focus by reviewing companies highlighted in the 10 dividend fortresses.
• Prioritize resilience and capital preservation with help from the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.